bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
CAU24

Order Name:
Calcium (U-24 hrs)

 
Useful For:
  1. Evaluation of calcium oxalate and calcium phosphate kidney stone risk, and calculation of urinary supersaturations
  2. Evaluation of bone diseases, including osteoporosis and osteomalacia
 
Methodology:
Arsenazo III
 
AliasesName:
Ca (Calcium), U-24 hrs.
 
 
 
Test Code:
CAU24

Order Name:
Calcium (U-24 hrs)

 
Collection Specimen Or Container:
24-hour urine, Clean containner with preservative
Preservative -  can be selected as list below:
  1. 20 mL of 6N HCL (Preferred) or
  2. 10 mL of 25% HCl or
  3. non preservative if order with Protein (U-24 hrs) or Microalbumin ( U-24 hrs)
Note:
  • Please keep in refrigerated (2-8°C) during collection and transportation
  • 24-hours volume is required.
 
Specimen Testing Type:
24-hour urine, minimum volume 10 mL
 
Sub Mission Container:
Clean container
 
Rejection Criteria:
Hemolysis: 4+ reject
Other: Wrong preservative type will be reject
 
Specimen Stabillity:
Specimen Type Temperature Time
24-hours urine Rerigerated, 2oC to 8oC 4 days
Frozen, -20oC 21 days
 
 
 
Test Code:
CAU24

Order Name:
Calcium (U-24 hrs)

 
Method detail:
Arsenazo III
 
Schedule:
Tested daily (24 hours)
 
Turnaround Time:
Collected specimen to report within 1.5 hours (90 mins)
 
Performing Location:
Chemistry, Laboratory Department Tel. 13224
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
CAU24

Order Name:
Calcium (U-24 hrs)

 
 
Clinical Information:
The majority of calcium in the body is present in bones. The remainder of the calcium is in serum and has various functions. For example, calcium ions decrease neuromuscular excitability, participate in blood coagulation, and activate some enzymes.

Hypercalcemia can result from hyperparathyroidism, hypervitaminosis D, multiple myeloma, and some neoplastic diseases of bone. Long-term lithium therapy has been reported to cause hyperparathyroidism in some individuals, with resulting hypercalcemia.

Hypocalcemia can result from hypoparathyroidism, hypoalbuminemia, renal insufficiency, and pancreatitis.
 
Reference Value:
100 – 300 mg/day
 
Interpretation:
Increased urinary calcium excretion (hypercalciuria) is a known contributor to kidney stone disease and osteoporosis. Many cases are genetic (often termed "idiopathic"). Previously such patients were often divided into fasting versus absorptive hypercalciuria depending on the level of urine calcium in a fasting versus fed state, but the clinical utility of this approach is now in question. Overall, the risk of stone disease appears increased when 24-hour urine calcium is >250 mg in men and >200 mg in women. Thiazide diuretics are often used to reduce urinary calcium excretion, and repeat urine collections can be performed to monitor the effectiveness of therapy. Known secondary causes of hypercalciuria include hyperparathyroidism, Paget disease, prolonged immobilization, vitamin D intoxication, and diseases that destroy bone (such as metastatic cancer or multiple myeloma). Urine calcium excretion can be used to gauge the adequacy of calcium and vitamin D supplementation, for example in states of gastrointestinal fat malabsorption that are associated with decreased bone mineralization (osteomalacia).
 
Clinical Reference:
  1. Manufacturer’s reagent package insert, Architect® Calcium, ABBOTT Laboratories, Abbott Park IL 60064 USA, January 2016.
  2. www.mayomedicallaboratories.com